WALTHAM, Mass • 2024-02-27

Frost & Sullivan Recognizes BostonGene with Frost & Sullivan’s Enabling Technology Leadership Award for Revolutionizing Precision Oncology Diagnostics

5 min to read

BostonGene honored as thought leader in precision oncology, driving the evolution of personalized cancer care through integrative multi-omic diagnostic technologies
WALTHAM, Mass – February 27, 2024 – BostonGene, a leading provider of molecular and immune profiling solutions, has been awarded the 2024 Frost & Sullivan Enabling Technology Leadership Award.

The analyst firm uses a rigorous analytical process to evaluate nominees before determining the award recipient. Frost & Sullivan identifies companies that develop growth strategies based on a visionary understanding of the future and effectively address new challenges and opportunities by deploying best practices and strategic analytics across a value chain.

“Frost & Sullivan recognizes that BostonGene is at the forefront of oncological innovation, exemplified by its groundbreaking progress in next-generation sequencing, digital image analysis, and immunoprofiling,” said Natalia Casanovas, Best Practices Research Analyst at Frost & Sullivan. “With a commitment to precision and excellence, BostonGene’s diagnostic technologies and approaches underscore its dedication to advancing the field of oncology, offering comprehensive solutions that redefine the landscape of personalized cancer care.”

From pioneering first-in-human clinical trials to strategic partnerships addressing specific cancer types, BostonGene’s multidisciplinary approach demonstrates its commitment to tailoring treatment strategies and elevating patient care. Trailblazing innovations in cancer care technologies position BostonGene as an industry leader. BostonGene is reshaping the landscape of precision medicine by strategically focusing on novel research and impactful solutions, expanding personalized medicine beyond the limits of oncology.

“We are honored to receive this award recognizing our multi-omics approaches and AI/ML-enabled solutions, which are becoming industry standards for biomarker analysis, patient stratification in drug development and accelerating innovation. These technologies are driving a transformative shift, fostering the next generation of diagnostic approaches in precision oncology, “said Andrew Feinberg, President and CEO of BostonGene.

About BostonGene Corporation

BostonGene has a mission to provide transformative, AI-integrated molecular analytics and biomarker discovery for precision matching of therapies to improve the lives of patients living with cancer and other immune-related diseases. BostonGene’s service model provides customized client solutions using a multi-omic approach prioritized for real-world impact, including optimized standard-of-care therapies, accelerated research and cost-effective, measurable results. BostonGene’s tests reveal key drivers of each patient’s unique disease profile, including an in-depth profile of the immune microenvironment, actionable mutations, biomarkers of response to diverse therapies, and recommended therapies. Through these comprehensive analyses, BostonGene’s tests generate a personalized roadmap for therapeutic decision-making for each patient. For more information, visit BostonGene at http://www.BostonGene.com.

Erin O’Reilly

Senior Director